Moreover, iRGD exo-si showed stronger CPT1A inhibition than exo-si both in vitro and in vivo, suggesting that iRGD-modified exosomes are a better candidate for siRNA targeting colon cancer. Here, CPT1A is linked to colonic neoplasm.